Greater Manchester Medicines Management Group

Greater Manchester Clinical Standards Board

NHS

News Summary

From this page you will be able to access a summary of additions or changes to the GMMMG website on a monthly basis

August 2019

 

Formulary and Managed Entry Subgroup (FMESG)

19.8.19

Chapter 13 of the GM formulary has been updated to reflect the new and updated GM primary care dermatology pathways. Changes include:

  • Updated options for mild potency topical steroids
  • Updated potent topical steroids with salicylic acid
  • Calcipotriol/betamethasone foam (Enstilar®) added to formulary, for management of scalp psoriasis when first-line options do not produce a satisfactory response.
  • Isotretinoin/erythromycin gel (Isotrexin®) added to formulary

12.8.19

The following FMESG actions for July 2019 have been proposed and will be sent to CSB for support. We now seek comments on these proposals.  This consultation is open until 5pm on Monday 23rd September 2019.

High Cost Drugs Subgroups

12.8.19

On behalf of the GMMMG HCD Groups, a Greater Manchester-wide commissioning statement for Bezolotoxumab  (Zinplava®) for the Prevention of Recurrence of Clostridium Difficile Infection in Adults at High Risk of Recurrence is in development. 

The statement has been developed in line with the information currently available and aims to prevent variation in prescribing of this agent across GM. Updated guidance from PHE is pending and the planned NICE TA has been suspended as the manufacturer failed to submit the necessary information. GMMMG feel that the place in therapy for this agent is unclear and so seek the views of the GM health economy and population. There is no proposed financial and commissioning impact as this agent is not recommended for prescribing, however additional information is included within the statement.

We now seek comments on this draft. This consultation period is open until 5pm on Monday 23rd of September.

12.8.19

On behalf of the GMMMG HCD Groups, a Greater Manchester-wide commissioning statement for Fidaxomicin (Dificlir®) for the Treatment of Clostridium Difficile Infection is in development. 

A formal commissioning policy is required as fidaxomicin was added to the PBR Tariff Excluded Drugs List as a CCG commissioned drug from the 1st April 2019. Fidaxomicin is currently included on the GMMMG RAG list as a green plus drug, on the advice of microbiology. There is no change in the route of access proposed by this statement; it is the payment mechanism which has changed.

We now seek comments on this draft. This consultation period is open until 5pm on Monday 23rd of September.

<< Back

Line

TERMS AND CONDITIONS    |    CONTACT US    |    ABOUT US    |    ARCHIVE

RSS Feed
 
spacer